The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
The effects of benazepril, a new angiotensin‐converting enzyme inhibitor, in mild to moderate essential hypertension: A multicenter study
Benazepril hydrochloride is a new angiotensin‐converting enzyme inhibitor . In a multicenter study , 206 patients with mild to moderate hypertension were r and omized to receive benazepril at a dose of 2 , 5 , 10 , or 20 mg , hydrochlorothiazide , 25 mg , or placebo once daily for 4 weeks . The 20 mg dosage of benazepril  lowered blood pressure to a degree equal to that of 25 mg hydrochlorothiazide : −12.217.7 mm Hg and −13.4/−7.5 mm Hg , respectively . Hydrochlorothiazide proved to be more effective in black subjects . At lower dosage levels of benazepril ( 2 , 5 , and 10 mg ) , blood pressure reduction was not significantly different from that with placebo . In those patients who failed to achieve goal diastolic blood pressure of < 90 mm Hg with monotherapy after 4 weeks , the addition of open‐label hydrochlorothiazide ( 25 mg/day ) to benazepril , hydrochlorothiazide , or placebo produced a substantial additional decrease in blood pressure over a 2‐week period . No definite adverse effects on hématologie measurements , serum biochemistry test results , or urinalyses were noted . Subjective adverse experiences were common in all groups but except in three or possibly four instances were not considered causally related to the study drug
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .